These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31282771)

  • 1. Switching patients in the age of long-acting recombinant products?
    Escobar M; Santagostino E; Mancuso ME; Coppens M; Balasa V; Taylor JA; Iorio A; Negrier C
    Expert Rev Hematol; 2019; 12(sup1):1-13. PubMed ID: 31282771
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparing Factor Use and Bleed Rates in U.S. Hemophilia A Patients Receiving Prophylaxis with 3 Different Long-Acting Recombinant Factor VIII Products.
    Simpson ML; Desai V; Maro GS; Yan S
    J Manag Care Spec Pharm; 2020 Apr; 26(4):504-512. PubMed ID: 32020842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Real-World Analysis of Commonly Prescribed FVIII Products Based on U.S. Medical Charts: Consumption and Bleeding Outcomes in Hemophilia A Patients.
    Yan S; Maro GS; Desai V; Simpson ML
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1258-1265. PubMed ID: 32820685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ; Obaji SG; Collins PW
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience of switching patients with severe hemophilia to rVIII-SingleChain or rIX-FP.
    Oldenburg J; Pipe SW; Mancuso ME; Klamroth R; Hassoun A; Olivieri M; Goldmann G; Kenet G; Miesbach W; Schmiedl J; Hegemann I
    Curr Med Res Opin; 2023 Feb; 39(2):219-225. PubMed ID: 36170120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Utilisation and Bleed Rates in Patients with Haemophilia B Who Switched to Recombinant Factor IX Fusion Protein (rIX-FP): A Retrospective International Analysis.
    Hermans C; Marino R; Lambert C; Mangles S; Sommerer P; Rives V; Maro G; Malcangi G
    Adv Ther; 2020 Jun; 37(6):2988-2998. PubMed ID: 32333327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, efficacy and pharmacokinetics of rVIII-SingleChain in children with severe hemophilia A: results of a multicenter clinical trial.
    Stasyshyn O; Djambas Khayat C; Iosava G; Ong J; Abdul Karim F; Fischer K; Veldman A; Blackman N; St Ledger K; Pabinger I
    J Thromb Haemost; 2017 Apr; 15(4):636-644. PubMed ID: 28166608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 11. Population pharmacokinetics of a new long-acting recombinant coagulation factor IX albumin fusion protein for patients with severe hemophilia B.
    Zhang Y; Roberts J; Bensen-Kennedy D; Jacobs I; Santagostino E; Voigt C; Feussner A; Morfini M; Sidhu J
    J Thromb Haemost; 2016 Nov; 14(11):2132-2140. PubMed ID: 27513989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Personalized prophylaxis.
    Collins PW
    Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis in real life scenarios.
    Fischer K; Konkle B; Broderick C; Kessler CM
    Haemophilia; 2014 May; 20 Suppl 4():106-13. PubMed ID: 24762285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
    Guillet B; Yan S; Hooper B; Drelich D; Steenkamp J; Tomic R; Mancuso ME
    Adv Ther; 2024 Feb; 41(2):649-658. PubMed ID: 38070040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging drugs for the treatment of hemophilia A and B.
    Morfini M; Zanon E
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):301-13. PubMed ID: 27547884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?
    Hazendonk HCAM; van Moort I; Mathôt RAA; Fijnvandraat K; Leebeek FWG; Collins PW; Cnossen MH;
    Blood Rev; 2018 Jul; 32(4):265-271. PubMed ID: 29426727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Safety and Efficacy of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Previously Treated Pediatric Patients with Hemophilia B: Results from a Phase 3b Extension Study.
    Kenet G; Chambost H; Male C; Halimeh S; Lambert T; Li Y; Seifert W; Santagostino E
    Thromb Haemost; 2020 Apr; 120(4):599-606. PubMed ID: 32185782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioneering designs for recombinant coagulation factors.
    Schulte S
    Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.